MaxCyte, Inc. (MXCT) Profit Margins
Over the twelve months to 2026-06-30, MaxCyte, Inc. (MXCT) had gross margin 79.2%, operating margin -134.6%, net margin -114.8%, free cash flow margin -76.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MXCTMaxCyte, Inc.Follow MXCT — free
—
Price chart with a free account
- Market cap
- 144.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% | 79.2% | |
| Operating margin | -53.7% | -61.8% | -117.0% | -132.5% | -157.1% | -134.6% | |
| Net margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% | -114.8% | |
| FCF margin | -42.8% | -75.1% | -61.5% | -75.8% | -109.5% | -76.1% |
USD millions · SEC XBRL
MaxCyte, Inc. — questions
- What is MaxCyte, Inc.'s gross margin?
- 79.2% over the twelve months to 2026-06-30.
- What is MaxCyte, Inc.'s operating margin?
- -134.6% over the twelve months to 2026-06-30.
- What is MaxCyte, Inc.'s net profit margin?
- -114.8% over the twelve months to 2026-06-30.
Every figure on this page comes from MaxCyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.